Phaseline

Companies › Alethia Biotherapeutics

Alethia Biotherapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sotevtamab
Anti-tumor-associated secreted clusterin (TA-sCLU) monoclonal antibody
CLUPhase 2Metastatic Colorectal Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06225843SotevtamabPhase 2Metastatic Colorectal CancerOncologyMar 2026

Targets

CLU (1)

Companies with the same targets

–

Companies built like this

CatalYm Solstice Oncology CrystalGenomics Partner Therapeutics STCube

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.